Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy

Phase 1

Completed

• Conditions: Perennial Allergic Rhinoconjunctivitis; Allergic Asthma
• Interventions: Biological: CYT005-AllQbG10

• Registration Number: NCT00652223
• Lead Sponsor: Cytos Biotechnology AG

Brief Summary

The purpose of the study is to test the safety, tolerability, immunogenicity and clinical efficacy of the combination treatment AllQbG10 in patients with rhino-conjunctivitis and asthma due to house dust mite allergy in a single-center, open-label setting.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-03
• Study Completion: 2005-11
• Status Verified: 2008-04
• Study First Submitted: 2008-04-01
• Study First Submitted QC: 2008-04-01
• Study First Posted: 2008-04-03
• Last Update Submitted: 2008-04-04
• Last Update Posted: 2008-04-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

• Mild to moderate perennial allergic rhinoconjunctivitis due to sensitization against house dust mites
• Mild asthma
• Females only if non-reproductive or agree to practice an effective and accepted method of contraception

Exclusion Criteria

• Relevant cardiovascular, renal, pulmonary or endocrine disease
• History of autoimmune disease
• Severe allergies
• History of active infectious disease
• Current diagnosis or history of malignancy
• Relevant neurological or psychiatric disorder
• Pregnancy or lactation
• History of alcohol abuse or other recreational drugs
• Use of an investigational drug within three month before enrolment
• Blood donation within 30 days before enrolment

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1	CYT005-AllQbG10	-

Trial Locations

Locations (1)

University Hospital Zurich, Department of Dermatology; 🇨🇭 Zurich, Switzerland